TRE-515 has received FDA fast track designation for treating PSMA-positive mCRPC, aiming to accelerate its development and availability. The drug is being tested in combination with Pluvicto, a ...
HLD-0915 has received FDA fast track designation for mCRPC, expediting its development and review process to address unmet medical needs. Halda Therapeutics is conducting a phase 1/2 clinical trial to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback